Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia.
EX1 net income for the last quarter is −1.61 M AUD, while the quarter before that showed −2.71 M AUD of net income which accounts for 40.53% change. Track more EXOPHARM LIMITED financial stats to get the full picture.
Today EXOPHARM LIMITED has the market capitalization of 4.83 M, it has increased by 10.00% over the last week.
No, EX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EXOPHARM LIMITED stock right from TradingView charts — choose your broker and connect to your account.
EX1 reached its all-time high on Apr 14, 2021 with the price of 2.212 AUD, and its all-time low was 0.020 AUD and was reached on Jun 15, 2023. See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EXOPHARM LIMITED technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EXOPHARM LIMITED stock shows the sell signal. See more of EXOPHARM LIMITED technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.